Key Points Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company has made investments and acquisitions to strengthen its future growth prospects. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one d ...